Eton Pharmaceuticals, Inc. (ETON) Financial Ratios

Eton Pharmaceuticals, Inc. (ETON) has an ST Score of 54.9 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate ETON a Buy, with a price target of $72.00 (+43.5% vs the current price). Our ST Score grades it B- (54.9/100). The ST Score is a data-driven signal, not a recommendation.

Valuation F, Profitability A, Financial Strength D+, Momentum B, Growth A-, Forecast C+.

Eton Pharmaceuticals, Inc. (ETON) earns a valuation grade of F, measured against Drug Manufacturers - Specialty & Generic peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Eton Pharmaceuticals, Inc. (ETON) earns a growth grade of A-, measured against Drug Manufacturers - Specialty & Generic peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Eton Pharmaceuticals, Inc. (ETON) earns a profitability grade of A, measured against Drug Manufacturers - Specialty & Generic peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Eton Pharmaceuticals, Inc. (ETON) earns a financial strength grade of D+, measured against Drug Manufacturers - Specialty & Generic peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Eton Pharmaceuticals, Inc. (ETON) is $72.00 from 7 analysts, which is +43.5% versus the recent price of $50.19.

Eton Pharmaceuticals, Inc. (ETON) has a Piotroski F-Score of 7 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.